

Table II. Efficacy outcomes reported in included studies

| Study | Study group | Muscle tone ^a | | | Spasms | | | Disability | Subjective impression improvement, % | | |
|---|-------------|--|---------------------|---------------------------|--|---------------------|---------------------------|--|--------------------------------------|-------------------|-----------------|
| | | Improvement compared with baseline, % patients | Baseline, Mean (SD) | Post-treatment, Mean (SD) | Improvement compared with baseline, % patients | Baseline, Mean (SD) | Post-treatment, Mean (SD) | Improvement compared with baseline, % patients | Overall | Patient or parent | Investigator |
| <i>Baclofen vs placebo</i> | | | | | | | | | | | |
| Multiple sclerosis | | | | | | | | | | | |
| Hudgson & Weightman, 1971 (31) | BAC | — | — | — | — | — | — | — | 57 | — | — |
| | PLA | — | — | — | — | — | — | — | 22 | — | — |
| Duncan et al., 1976 (25) | BAC | 55 ^b | — | — | 72 ^b | — | — | — | — | 64 ^c | 64 ^c |
| | PLA | 5 | — | — | 11 | — | — | — | — | 9 | 0 |
| Sachais et al., 1977 (30) | BAC | — | — | — | 42 ^b | — | — | — | — | — | — |
| | PLA | — | — | — | 16 | — | — | — | — | — | — |
| Feldman et al., 1978 (26) | BAC | 65.2 ^b | — | — | 56.3 ^b | — | — | 34.8 ^b | — | — | — |
| | PLA | 17.4 | — | — | 6.3 | — | — | 30.4 | — | — | — |
| Sawa & Paty, 1979 (27) | BAC | 72 ^b | — | — | — | — | — | — | — | — | — |
| | PLA | 0 | — | — | — | — | — | — | — | — | — |
| Brar et al., 1991 (32) | BAC | 30 | — | — | — | — | — | 17 | — | — | — |
| | BAC + EXER | 40 | — | — | — | — | — | 23 | — | — | — |
| | EXER | 17 | — | — | — | — | — | 23 | — | — | — |
| | PLA | 20 | — | — | — | — | — | 20 | — | — | — |
| Ørsnes et al., 2000 (46) | BAC | — | 1.9 (1.5) | 2.8 (2.4) | — | — | — | — | — | — | — |
| | PLA | — | 3.1 (2.1) | 3.2 (2.3) | — | — | — | — | — | — | — |
| Cerebral palsy | | | | | | | | | | | |
| Milla & Jackson, 1977 (28) | BAC | 70 ^b | — | — | — | — | — | — | — | 70 ^c | 60 ^c |
| | PLA | 10 | — | — | — | — | — | — | — | 5 | 0 |
| McKinley et al., 1980 (33) | BAC | 70 | — | — | — | — | — | — | — | — | — |
| | PLA | 25 | — | — | — | — | — | — | — | — | — |
| Stroke | | | | | | | | | | | |
| Medaer et al., 1991 (29) | BAC | — | — | 2.95 (0.61) ^b | — | — | — | — | — | — | — |
| | PLA | — | — | 3.75 (0.72) | — | — | — | — | — | — | — |
| <i>Baclofen vs active comparators or open-label</i> | | | | | | | | | | | |
| Multiple sclerosis | | | | | | | | | | | |
| Smolenski et al., 1981 (34) | BAC | 82.5 | — | — | 60 | — | — | — | 30 | — | — |
| | TIZ | 68.5 | — | — | 50 | — | — | — | 18 | — | — |
| Newman et al., 1982 (35) | BAC | 30.8 | — | — | — | — | — | — | — | — | — |
| | TIZ | 34.6 | — | — | — | — | — | — | — | — | — |
| Stien et al., 1987 (36) | BAC | 65 | — | — | 65 | — | — | — | — | — | — |
| | TIZ | 72 | — | — | 67 | — | — | — | — | — | — |
| Bass et al., 1988 (44) | BAC | — | — | — | — | — | — | 8.3 | — | — | — |
| | TIZ | — | — | — | — | — | — | 14.6 | — | — | — |
| Eyssette et al., 1988 (37) | BAC | 51.2 | — | — | 43.3 | — | — | — | — | — | — |
| | TIZ | 58.0 | — | — | 55.2 | — | — | — | — | — | — |
| Hoogstraten et al., 1988 (38) | BAC | 64.5 | — | — | 72.7 | — | — | — | 35.7 | — | — |
| | TIZ | 57.1 | — | — | 57.2 | — | — | — | 35.7 | — | — |
| Cartledge et al., 1974 (45) | BAC | — | — | — | — | — | — | — | — | 51.3 | 48.6 |
| | DIA | — | — | — | — | — | — | — | — | 40.5 | 35.1 |
| From & Hudgson, 1975 (43) | BAC | — | — | — | 83.3 | — | — | — | 75 ^b | — | — |
| | DIA | — | — | — | 85.7 | — | — | — | 0 | — | — |
| Spinal cord injury | | | | | | | | | | | |
| Jones & Lance, 1976 (23) | BAC | 87.3 | — | — | 88.6 | — | — | — | — | — | — |

Table II cont.

| Study | Study group | Muscle tone ^a | | | Spasms | | | Disability | Subjective impression improvement, % | | |
|-----------------------------|-------------|--|---------------------|---------------------------|--|---------------------|---------------------------|--|--------------------------------------|-------------------|--------------|
| | | Improvement compared with baseline, % patients | Baseline, Mean (SD) | Post-treatment, Mean (SD) | Improvement compared with baseline, % patients | Baseline, Mean (SD) | Post-treatment, Mean (SD) | Improvement compared with baseline, % patients | Overall | Patient or parent | Investigator |
| Nance et al., 1994 (39) | BAC | — | 3.7 (0.1) | 2.9 (0.1) | — | — | — | — | — | — | |
| | CLO | — | 3.7 (0.1) | 2.9 (0.1) | — | — | — | — | — | — | |
| | CYP | — | 3.7 (0.1) | 3.1 (0.1) | — | — | — | — | — | — | |
| Aydin et al., 2005 (40) | BAC | — | 19.2 (3.7) | 14.4 (6.4) ^d | — | 3.3 (0.9) | 2.3 (0.3) ^d | — | — | — | |
| | TENS | — | 20.1 (4.0) | 16.3 (2.8) ^d | — | 3.1 (0.7) | 2.6 (0.6) ^d | — | — | — | |
| Cerebral palsy | | | | | | | | | | | |
| Bresolin et al., 2009 (41) | BAC | — | 1.58 | 0.91 ^d | — | — | — | — | — | 2.9 | 2.9 |
| | EPE | — | 1.53 | 0.82 ^d | — | — | — | — | — | 21.6 | 8.1 |
| Brain injury | | | | | | | | | | | |
| Medici et al., 1989 (42) | BAC | 90.9 ^d | — | — | 83.3 | — | — | 43/20 ^e | — | — | — |
| | TIZ | 85.7 ^d | — | — | 57.1 | — | — | 40/21 ^e | — | — | — |
| Meythaler et al., 2004 (24) | BAC | — | 3.5 (1.1) | 3.2 (1.2) ^d | — | 1.1 (1.2) | 1.2 (1.3) | — | — | — | |

^aAssessed using the Ashworth scale or similar instrument; ^b $p \leq 0.05$ vs comparator; ^cstated as "significant" or "superior", but no p -value provided; ^d $p \leq 0.05$ vs baseline; ^eupper/lower extremities. BAC: baclofen; CLO: clonidine; CYP: cyproheptadine; DIA: diazepam; EPE: eperisone; EXER: exercises; PLA: placebo; TENS: transcutaneous electrical nerve stimulation; TIZ: tizanidine.